Patent application number | Description | Published |
20080233646 | Human DR4 antibodies and uses thereof - Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided. | 09-25-2008 |
20090010924 | Apoptotic Anti-IgE Antibodies - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 01-08-2009 |
20090220504 | COMBINATORIAL THERAPY - The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them. | 09-03-2009 |
20100136624 | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method - A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind. | 06-03-2010 |
20100273257 | Apo-2DcR - Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided. | 10-28-2010 |
20100316596 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING - Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided. | 12-16-2010 |
20110002933 | DR4 ANTIBODIES AND USES THEREOF - Death Receptor 4 (DR4) antibodies are provided. The DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided. | 01-06-2011 |
20110008354 | ANTIBODIES TO APO-2 RECEPTOR POLYPEPTIDES - Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. | 01-13-2011 |
20110268727 | ANTI-INTERFERON-ALPHA ANTIBODIES - The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). | 11-03-2011 |
20120144512 | TRANSGENIC ANIMALS EXPRESSING HUMAN IGE-M1' - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 06-07-2012 |
20120149881 | APOPTOTIC ANTI-IGE ANTIBODIES - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 06-14-2012 |
20120178127 | Nucleic acid encoding apoptotic anti-ige antibodies - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 07-12-2012 |
20120195908 | COMBINATORIAL THERAPY - The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them. | 08-02-2012 |
20120244148 | ANTI-INTERFERON-ALPHA ANTIBODIES - The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). | 09-27-2012 |
20130224146 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING - Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided. | 08-29-2013 |
20140004038 | COMBINATORIAL THERAPY | 01-02-2014 |
20140115729 | APOPTOTIC ANTI-IGE ANTIBODIES - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 04-24-2014 |